Symptoms and quality of life in late stage Parkinson syndromes: a longitudinal community study of predictive factors by Higginson, Irene J et al.
Symptoms and Quality of Life in Late Stage Parkinson
Syndromes: A Longitudinal Community Study of
Predictive Factors
Irene J. Higginson1*, Wei Gao1*, Tariq Zaffer Saleem1, K. Ray Chaudhuri2,3, Rachel Burman1,
Paul McCrone2, Peter Nigel Leigh2
1Cicely Saunders Institute, King’s College London, London, United Kingdom, 2 Institute of Psychiatry, King’s College London, London, United Kingdom, 3National
Parkinson Foundation International Centre of Excellence, Kings College Hospital, London, United Kingdom
Abstract
Background: Palliative care is increasingly offered earlier in the cancer trajectory but rarely in Idiopathic Parkinson’s
Disease(IPD), Progressive Supranuclear Palsy(PSP) or Multiple System Atrophy(MSA). There is little longitudinal data of
people with late stage disease to understand levels of need. We aimed to determine how symptoms and quality of life of
these patients change over time; and what demographic and clinical factors predicted changes.
Methods:We recruited 82 patients into a longitudinal study, consenting patients with a diagnosis of IPD, MSA or PSP, stages
3–5 Hoehn and Yahr(H&Y). At baseline and then on up to 3 occasions over one year, we collected self-reported
demographic, clinical, symptom, palliative and quality of life data, using Parkinson’s specific and generic validated scales,
including the Palliative care Outcome Scale (POS). We tested for predictors using multivariable analysis, adjusting for
confounders.
Findings: Over two thirds of patients had severe disability, over one third being wheelchair-bound/bedridden. Symptoms
were highly prevalent in all conditions - mean (SD) of 10.6(4.0) symptoms. More than 50% of the MSA and PSP patients died
over the year. Over the year, half of the patients showed either an upward (worsening, 24/60) or fluctuant (8/60) trajectory
for POS and symptoms. The strongest predictors of higher levels of symptoms at the end of follow-up were initial scores on
POS (AOR 1.30; 95%CI:1.05–1.60) and being male (AOR 5.18; 95% CI 1.17 to 22.92), both were more predictive than initial
H&Y scores.
Interpretation: The findings point to profound and complex mix of non-motor and motor symptoms in patients with late
stage IPD, MSA and PSP. Symptoms are not resolved and half of the patients deteriorate. Palliative problems are predictive
of future symptoms, suggesting that an early palliative assessment might help screen for those in need of earlier
intervention.
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Introduction
Idiopathic Parkinson’s Disease(IPD), Progressive Supranuclear
Palsy(PSP) and Multiple System Atrophy(MSA) share many
symptoms and signs in common, have profound motor and non-
motor symptoms and effects on quality of life, health care and
personal costs [1–5]. Symptoms include instability, fatigue,
dribbling, pain, psychological distress, cognitive impairment and
their prevalence correlates with Hoehn and Yahr stage [1,6–8].
However, little is known about how symptoms, quality of life and
impacts evolve in the later stages of these disorders.
We searched PubMed for articles using the keywords: (late stage
OR advanced OR palliative OR terminal care OR end of life)
AND (Parkinson’s OR MSA OR PSP) AND (longitudinal OR
cohort) AND (quality of life OR Symptoms OR psychological
distress).
Longitudinal data are rare and focussed on mild to moderate
disease often during treatments [1,6,7,9–11]. The NNIPPS study,
a randomised trial of Riluzole in MSA and PSP provides valuable
information on the progression of disease, survival, cognition and
some symptoms [5,8,12,13], but not the wide range of motor and
non-motor problems that can be experienced in late stage disease
[14]. Palliative care is offered to cancer patients early in the disease
course and to people affected by amyotrophic lateral sclerosis in
later stages of illness [15–17]. In contrast, few patients with even
late stage IPD, PSP or MSA have access to palliative care or
hospice services [17]. Lack of information about the trajectory of
symptoms and quality of life in late stage IPD, PSP and MSA
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means that it is not clear: (a) whether patients’ and care-givers’
needs are adequately met by existing services or whether
augmentation by specialist palliative care services would be
helpful; and (b) if the latter is the case, what would be the optimal
strategy for referral in relation to patient and care-giver needs and
disease evolution? Cross sectional studies of patients at different
stages can be biased and oversimplify the course of illness [18,19].
Thus longitudinal studies that consider individual trajectories are
likely to provide more accurate insights into patient needs and
factors that might predict likely needs for referral.
In this study we sought to answer two questions: a) how do
symptoms (especially those common in palliative care and at the
end of life in other conditions, such as pain, breathlessness, fatigue,
psychological distress) [20,21] and quality of life of Parkinson
syndrome patients change over time; and b) what demographic
and clinical factors predict these changes. The unique nature of
this study is the focus on palliative care needs, late stage disease
and home settings.
Methods
We conducted a longitudinal study over one year in community
settings. The study was approved by the Research Ethics
Committee of the Institute of Psychiatry and the Research Ethics
Committee of King’s College Hospital NHS Foundation Trust.
The study was conducted according to the principles expressed
in the Declaration of Helsinki and all procedures were approved
by both the Research Ethics Committee of the Institute of
Psychiatry and the Research Ethics Committee of King’s College
Hospital NHS Foundation Trust. All participants were given full
information regarding the study, signed to indicate their consent to
take part, and could withdraw at any time. Participation,
withdrawal or not, had no effect on the health care or other
services received. All comments and information was kept
confidential, and patient identifying information was not recorded
on the questionnaires, but kept separately from their consent
forms.
Participants
Patients were recruited from those attending King’s College
Hospital outpatient specialist neurology movement disorder clinic,
a secondary and tertiary clinic service with a geographical
catchment area of 4000 IPD patients altogether, covering South
East England (London, Kent, Sussex).
We recruited consenting patients attending the clinic with a
clinical diagnosis of IPD, MSA or PSP, who fell into stages 3–5 of
the Hoehn and Yahr system [22] for IPD and equivalent motor
disability for MSA and PSP. Patients were excluded if they were
already resident in nursing homes. When possible patients’ nearest
lay caregivers were also recruited.
Procedures for Baseline and Follow-up Interviews
Following recruitment we arranged baseline face to face
interviews in patients’ place of choice, usually their home. We
also interviewed the nearest caregiver or family members, in the
home or place of choice. Three follow-up interviews were
organised over the course of 12–15 months, aiming to conduct
interviews at 3–4 monthly intervals. Interviews invariably involved
travelling to patients homes, but we believed this would be
necessary for subjects with profound disability. We kept in touch
with patients by telephone and checked their condition with
clinical services before re-contacting them. Repeat visits were
agreed if, on arrival, the subject did not feel up to some of, or the
entire, interview. Patients were followed if they entered nursing or
care homes, hospices or hospital. Where possible we sought
information about any deaths that occurred. All interviews were
conducted by one of three centrally trained researchers with
psychology or palliative nursing backgrounds. The researchers
used a standard questionnaire to capture patients’ self-reported
demographic and clinical characteristics, the Hoehn and
Yahr(H&Y) classification (both as assessed and verified by
checking the clinical records), widely used to establish the staging
of IPD(21), symptoms and quality of life. Interviews took 1–
2 hours in the home; sometimes longer if the patients wanted to
take a break or had a lot to say. On occasions we returned for
interview, as on arrival it was not found to be a convenient time, or
to interview the caregiver. If patients had considerable difficulties
or distress when visited, the researcher followed a distress protocol,
to check that the patient/caregiver were happy to continue with
the interview and whether they wanted the researcher to make
contact with services for them. On a small number of occasions,
with the patient’s consent, the researcher contacted services on
their behalf for symptom problems or missed follow-up.
Clinical, Symptom, Psychological and Quality of Life
Assessments
Table 1 shows the measures administered at all time points.
Parkinson’s specific (PDQ-8) and generic measures (HADS-14,
EQ5D, POS, POS-PP) were used.
Outcome and Predictor Variables
Outcome were total scores on the POS-PP, the core POS (our
primary outcomes), the PDQ-8 and the HADs-14 at follow-up
interviews. Predictor variables were categorised into socio-demo-
graphic (age, sex, ethnic group, employment status, education,
living arrangement); clinical and health care related variables
(informal carer relationship, next of kin, disease type, stage of
disease, follow-up status, median time in study), and baseline
scores on the POS-PP, the core POS, the PDQ-8 and the HADs-
14. We also created four new outcome variables (ind_POS-PP,
ind_core-POS, ind_PDQ-8, ind_HADs-14). The values of these
new variables were determined by counting the number of follow-
up scores higher than the mean baseline score for that measure.
The new variables were in ordinal format with a value range of 0
to 3.
Statistical Analysis
Data were reported as means (SDs) or medians (ranges) if
continuous, and count (percent) if categorical. The group
trajectories of the total scores over time (the follow-up interviews)
were plotted for the POS-PP, the POS, the PDQ-8 and the HADs-
14. Ordinal logistic regression with the proportional odds
assumption was used to identify potential predictors of the high
follow-up scores. We first tested the bivariate association between
the new outcome variables (categorised into final outcome worse
than or better than the mean) and potential predictors (including
baseline scores of four instruments, and demographic and clinical
variables) using ordinal regression. Those predictors found to be
significant at the 0.2 level in bivariate analyses were used to build
multivariable models and to adjust for confounding effect between
predictors. Adjusted risk ratios (95% CI) were then estimated from
the multivariable models. We did not test the interaction effects
due to the small sample size. Analyses were performed for four
outcome variables separately. The main analyses included non-
missing data only. Analyses were repeated on multiple imputed
data. Sample size calculation was based on a mean difference of
0.5 (SD=1) in the primary outcome measures (POS-PP, Core-
Symptom and QoL Trajectories: Parkinson Syndromes
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POS) among subgroups or over time. We need a minimum 60
patients for a two-sided test detecting such difference with 80%
power and at a 5% significance level. Assuming prevalence of
symptoms in this patient population to be around 50%, 45 patients
would allow us to achieve a precision of 7% in the estimation of
symptom prevalence. Allowing for attrition at 25–30% over the
course of one year this would mean we needed to recruit 80–85
patients into the study. All statistical analyses were completed by
using SAS version 9.2 (SAS Institute, Inc., 2000 Cary, NC) and a
two-sided 0.05 was considered significant.
Results
Demographic and clinical characteristics
A total of 82 patients consented and were recruited into the
study over a period of 30 months (Table 2). Median disease
duration (range) was 8.0 years (1.0–25.0) from diagnosis [IPD:
5.8(1.0–25.0), MSA: 4.0(1.0–14.0), PSP: 2.7(1.0–11.0) years]. Over
two thirds of patients had at least severe disability – with over one
third being wheelchair-bound or bedridden; disability was higher
for PSP and MSA than IPD. Most patients (79) were unable to
work due to their illness, 65 had retired and only 4 were in current
part-time employment. Spouses were the most common carers –
35 patients had wife/partners and 24 had husband/partners who
acted as informal carers, all lived with their spouse/partner. 14
patients lived alone, of whom four had no informal carer although
formal care was in place for these patients.
Baseline symptoms, quality of life and psychological
problems
EQ5D and PDQ-8 scores showed poor quality of life (EQ5D
mean score = 0.4, PDQ-8= 42.8). Mean (SD) HADS-14 score was
21.6(5.0), and this did not differ between diagnoses, showing
considerable psychological distress. The total mean POS score was
moderate, approaching 14 out of a maximum of 40. Symptoms
were highly prevalent (table 3) in all conditions. POS-PP showed
patients reported a mean (SD) of 10.6(4.0) symptoms, with a mean
(SD) score overall of 22.1(9.9). Four symptoms were reported in
more than 80% of patients – problems using legs, fatigue/lack of
energy, feeling sleepy and pain. Nine further symptoms were
Table 1. The Parkinson’s specific and generic quality of life, symptom and palliative care measures administered at all time points.
Measure Number of items, content and scoring Validation/references
Parkinson’s Disease
Questionnaire(PDQ)-8
8 Items. Each item is rated: 0 (never) to 4(always/cannot do)
in the past one month. Items are: problems getting around
in public, difficulty dressing self, felt depressed, embarrassed
in public due to having disease, problems with close
personal relationships, problems with concentration,
unable to communicate with people properly, painful
muscle cramps or spasms. PDQ-8 Summary Index is
expressed as percentage of the sum of the items scores
on the maximum possible scale score [33].
Extensively validated in IPD and related disorders,
including translated versions and in different cultures,
provides a reliable measure of overall health status
recommended for studies in which a short questionnaire is
preferred [34–36]. It maps and shows a similar
responsiveness to change as the EQ5-D [33,37,38].
Hospital Anxiety and
Depression Scale(HADS)-14
14 items: 7 concerned with anxiety and 7 with depression.
Each item is rated on a 0–3 (worst) scale. Total possible
score is 42 (worst psychological distress).
HADS has been used widely in Parkinson syndromes and
many diseases. There are two subscales – depression and
anxiety but Rasch analysis in patients with Parkinson’s
Disease supports the use of total score to assess
psychological distress [39,40].
EQ5-D 5+2 items. EQ5-D has three components: 1) a descriptive
part, consisting of 5 items, that can then be converted into
a value (EQ-Index), each ranging from 1 (perfect health state)
to 0 (death); 2) a question about change in health status
in the preceding 12 months; and 3) a visual analogue scale
(EQ-VAS) for assessment of current health state, from 0, the
worse imaginable health state, to 100, best imaginable
health state.
ED5-D is a generic widely used HRQoL measure. It has
been used widely in IPD [37,38,41–43]. EQ5-D was
calculated using the UK weighting schemes
recommended by Dolan P et al [44].
Palliative care Outcome Scale (POS) 10 items. Each item is rated according to how much it has
affected the person, from 0 (best) to 4 (overwhelming
problem) over the past 2 weeks. Items are: pain control,
symptom control, patient anxiety, family anxiety, information,
sharing feelings, depression, self-worth, practical needs
and time wasted. Total possible score 40.
POS is one of the top two outcome measures used in
palliative care studies, has psychometric and clinimetric
validity, reliability and responsiveness to change, in late
stage and earlier but symptomatic disease across many
conditions and settings, including neurological conditions
(multiple sclerosis, motor neurone disease), cancer, organ
(respiratory, renal and heart) failure, elderly patients with
co-morbid disease, in home, hospital, nursing home,
hospice settings. Research has shown it can be used as an
overall scale, as individual items or 3 factors; physical,
quality of care and psychological [23,45–48].
Palliative care Outcome Scale for
Symptoms (POS-PP)
20 items (motor and non-motor symptoms). Each item is
rated according to how much it has affected the person,
from 0 (best) to 4 (overwhelming problem) over the past
2 weeks. Total possible score of 80.
A validated extension of the core POS assessing symptoms
(POS-S), with additional Parkinsonism Plus symptoms
added. POS-S measure has been used in many conditions,
including neurological diseases [24,45], and POS-PP is
essentially POS-S with some specific Parkinson’s related
symptoms added. There are no generic palliative care
measures that have been used and validated in IPD, MSA
or PSP; therefore POS and POS-PP because of their proven
validity in late stage disease and simplicity of use were the
best fit.
doi:10.1371/journal.pone.0046327.t001
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present in over half of patients - difficulty in communicating,
mouth problems (drooling), use of arms & hands, spasm/stiffness,
sleep problems, constipation, difficulty with bladder control,
problems swallowing and shortness of breath.
Table 2. Characteristics of the 82 patients, total and by diagnosis: IPD, MSA, PSP.
Characteristics Value IPD PSP MSA Total
All Total, n(%) 50(61%) 15(18%) 17(21%) 82(100%)
Gender Men n(%) 27(54%) 7(47%) 11(65%) 45(55%)
Age Mean(SD) 67(8) 69(11) 67(8) 67(9)
Median(min, max) 68(40, 80) 71(38, 86) 68(51,81) 68(38,86)
Ethnic group White UK 35(70%) 12(78%) 17(100%) 64(78%)
White Irish 2(4%) 0(0%) 0(0%) 2(2%)
South Asian 6(12%) 1(7%) 0(0%) 7(8%)
Black Caribbean 3(6%) 0(0%) 0(0%) 3(4%)
Chinese 1(2%) 0(0%) 0(0%) 1(1%)
Other 3(6%) 2(12.5%) 0(0%) 5(6%)
Employment Retired 38(76) 12(80%) 11(65%) 61(74%)
In employment or self-
employed
6(12%) 0(0%) 0(0%) 6(7%)
Unable to work (due to
illness)
6(12%) 3(20%) 6(35%) 15(18%)
Hoehn & Yahr* 3 20(40%) 2(13%) 2(12%) 24(29%)
4 19(38%) 4(26%) 7(41%) 30(37%)
5 11(22%) 9(60%) 8(47%) 28(34%)
Informal carer No informal carer 7(14%) 1(7%) 1(6%) 9(11%)
Spouse/Partner 36(72%) 11(73%) 12(71%) 59(72%)
Daughter 4(8%) 2(13%) 2(12%) 8(10%)
Sibling 2(4%) 1(7%) 1(6%) 4(5%)
All others 1(2%) 0(0%) 1(6%) 2(2%)
Living arrangements Lives alone 10(20%) 2(13%) 2(12%) 14(17%)
Lives with carer 36(72%) 13(87%) 14(82%) 63(77%)
Other 4(8%) 0(0%) 1(6%) 5(6%)
Baseline symptom and
quality of life
assessments Mean
(Mean, SD)
EQ-5D 0.47(0.59, 0.32) 0.31(0.27, 0.40) 0.29(0.26, 0.35) 0.40(0.52, 0.35)
EQ-5D Health Status 58.1(50.0,15.8) 49.0(50.0,17.1) 53.3(50.0,26.1) 55.9(50.0,17.8)
POS 13.7(14.5,5.7) 11.9(10.0,6.1) 14.3(16.0,4.5) 13.5914.5,5.6)
POS-PP 21.4(20.5,10.8) 20.4(23.0,10.0) 26.0(26.0,6.0) 21.9(24.0,10.1)
PDQ-8 43.2(46.0,20.1) 35.8(41.5,18.4) 47.6(50.0,16.4) 42.8(46.0,19.4)
HADS 22.6(23,4.1) 20.4(22.0,8.3) 19.4(19.5,4.2) 21.8(23.0,4.9)
Follow-up status at
study end
Still alive 39(78%) 7(47%) 7(41%) 53(65%)
Died 3(6%) 7(47%) 8(47%) 18(22%)
Too ill 1(2%) 1(7%) 1(6%) 3(4%)
Withdrew 4(8%) 0(0%) 1(6%) 5(6%)
Lost to follow-up 3(6%) 0(0%) 0(0%) 3(4%)
Duration of illness since
diagnosis (years)
Mean(SD) 11.9(5.8) 4.6(2.7) 5.9(4.0) 9.3(6.0)
Median (min, max) 5.8(1.0,25.0) 2.7(1.0,11.0) 4.0(1.0,14.0) 8.0 (1.0, 25.0)
*chi-squared comparison between groups = 11.5 df = 4, p = 0.021.
Hoehn & Yahr stage meaning is.
3 Mild to moderate bilateral disease; some postural instability; physically independent.
4 Severe disability; still able to walk or stand unassisted.
5 Wheelchair-bound or bedridden unless aided.
doi:10.1371/journal.pone.0046327.t002
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Longitudinal trajectories
For the longitudinal data, there was attrition in all disease
groups with loss of ,36% to follow-up interviews, between
baseline and 12 months for IPD, but more than 50% for MSA and
PSP, despite the fact that interviews were scheduled at the homes
of the patients. Some of this loss was related to deaths in the PSP
and MSA groups (Table 2).
Even for those who survived but could not be interviewed,
‘missingness’ is unlikely to be random (i.e. it is likely to be
associated with more severe disease). Most attrition was explicitly
as a result of death (18 patients) or illness (3 patients) (table 2),
although it may be that some of the 8 who withdrew or were lost to
follow-up also had greater illness.
Examination of plots of individual patient trajectories assessed
by POS, POS-PP,HADS and PDQ -8 (Figure 1, and figures
S1,S2,S3) reveals that, on average, subjects who remain in the
study (mostly IPD subjects, but also some people with PSP or
MSA) deteriorate or remain unchanged over the study. Half of the
patients showed either an upward (worsening, 24/60) or fluctuant
(8/60) trajectory for POS (palliative problems), POS-PP and
HADS.
Predictors of severe outcomes
Grouping patients according to their outcome of higher or
lower problems shows that those patients with severe problems at
the end of the final interview also had severe problems or
symptoms earlier during their illness (figure 2).
Table 4 shows the results of ordinal logistic regression models.
Of the demographic variables, only gender remained significant in
multivariable analysis, with men having a greater chance of
subsequent physical symptoms according to POS-PP(AOR: 5.18;
95%CI: 1.17 to 22.92). Gender had no effect on psychological
symptoms on HADS, or palliative problems on core POS. More
severe stage – as indicated by H&Y - was not significantly
predictive of severe symptoms subsequently. High initial palliative
problems (as indicated by POS) most consistently predicted future
problems on all the outcomes, although symptoms(POS-PP), poor
quality of life(PDQ-8) or psychological distress (as indicated by
HADs) also showed predictive effects. Imputed data showed
similar results. Figure 3 illustrates this, showing the relationship
between scores on the baseline POS and final POS-PP and the
single pain item.
Discussion
We found that people with late stage IPD, PSP and MSA, as
shown by H&Y stage 3-5, experience profound symptoms,
physical and psychological. The levels of symptoms and problems
were similar to, or more severe than, those entering palliative care
with cancer [18–21,23,24]. Common symptoms (affecting over
50%) were: problems using legs, fatigue/lack of energy, feeling
sleepy, pain, difficulty in communicating, mouth problems
(drooling), use of arms & hands, spasm/stiffness, sleep problems,
constipation, difficulty with bladder control, problems swallowing
and shortness of breath. Some of these symptoms, especially pain
and shortness of breath, have effective treatments in cancer
patients, which may need to be developed for Parkinson’s
syndromes. The levels of PDQ-8 and EQ5-D indicated poorer
quality of life than previous samples (even the sickest subgroups) of
people with Parkinson syndromes [2,6,9]. For the HADS, caseness
of anxiety or depression is considered when either sub-scale
achieves a score of greater than 8, with severe problems being
considered as over 21 on the total scale. Our median score was
more than this, suggesting that half of the sample had severe
Table 3. Prevalence (%) of symptoms in patients with different conditions at baseline interview.
Item Symptoms
IPD
n=50 (61%)
PSP
n= 15 (18%)
MSA
n= 17 (21%)
Total
N=82
1 Pain 86.0 60.0 88.2 81.7
2 Spasms 60.0 53.3 70.6 61.0
3 Fatigue/lack of energy 84.0 80.0 88.2 84.2
4 Shortness of breath 54.0 46.7 47.1 51.2
5 Nausea 24.0 6.7 41.2 24.4
6 Vomiting 8.0 0.0 5.9 6.1
7 Poor appetite 22.0 26.7 35.3 25.6
8 Problems swallowing 40.0 60.0 76.5 51.2
9 Mouth problems 70.0 66.7 82.4 72.0
10 Feeling sleepy 86.0 73.3 82.4 82.9
11 Difficulty in sleeping 58.0 40.0 82.4 59.8
12 Constipation 54.0 60.0 76.5 59.8
13 Difficulty with bowel control 24.0 20.0 58.8 30.5
14 Difficulty with controlling urine 52.0 46.7 70.6 54.9
15 Pressure sores 6.0 6.7 11.8 7.3
16 Problems using arms 64.0 73.3 82.4 69.5
17 Problems using legs 80.0 86.7 94.1 84.2
18 Difficulty communicating 58.0 80.0 76.5 65.9
19 Falls 36.0 53.3 47.1 41.5
20 Hallucinations 28.0 13.3 29.4 25.6
doi:10.1371/journal.pone.0046327.t003
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depression and/or anxiety. Over a third of the sample overall died
during the course of the study, suggesting that we had correctly
identified those with late stage disease. Survival was poorer for
people with MSA and PSP validating our diagnosis of these
patients and pointing to their more urgent needs. MSA and PSP
are rarely studied, as is stage 5 IPD which is frequently omitted in
clinical studies, thus the survival and symptom data for these
groups is especially valuable.
Over the course of one year, half of all patients deteriorated in
terms of symptom control and psychological or palliative distress.
Analyses of final symptom and quality of life assessments,
disappointingly, show that those with initial severe symptoms
continued to experience these. The initial scores on the Palliative
care Outcome Scale (POS) and the PDQ-8 predicted problems
later.
Given the long term nature of the symptoms and the different
courses, traditional models of palliative care used in cancer may
not be appropriate. However, in the USA a much higher
proportion of non cancer patients are referred to hospice care
than in the UK [25], suggesting that here at least solutions have
been found for non-cancer patients. Older patients and those from
lower socio-economic groups have been shown to miss out on
palliative care, with lower levels of health care spending [26]. This
would apply to many of those in our study. There are urgent needs
to address in the care for people with neurological diseases
approaching the end of life, including dementia. The prevalence of
these conditions is growing rapidly in our ageing populations.
Older people face particular challenges if they are to age and die
well in the place and manner of their choosing, especially those
who life alone [27], as was the case for 1 in 5 of our sample.
Mitchell et al highlight the need to design and test interventions
that promote high-quality, goal-directed care [28]. A new short-
term model of palliative care integrated with neurology, provided
earlier in the course of illness, has been tested in UK patients with
Multiple Sclerosis, and appeared to improve symptoms, reduce
caregiver burden and reduce costs by preventing hospital
Figure 1. Individual trajectories of total scores of Palliative care Outcome Scale (POS). Note: Increased score equals more palliative
problems/needs, only patients with 4 assessments plotted.
doi:10.1371/journal.pone.0046327.g001
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admission [29,30]. While neurologists may be reluctant to
introduce the term ‘Palliative care’ to patients, in Germany a
recent survey of 573 patients severely affected by multiple sclerosis
found that 64% wanted disease progression and death and dying
to be addressed by their doctor [31]. Doctors who were
retrospectively viewed as avoiding raising critical aspects of the
illness were perceived as less empathetic [31]. ‘Short term’
palliative care could undertake assessment, and address symptoms,
psychological needs, end of life decision making and care co-
ordination using specialist palliative care staff, integrated with
neurology, rehabilitation and primary care teams. The aim would
be to quickly resolve problems and discharge patients after 4–6
weeks, providing education and care plans with existing services.
For many patients who are deteriorating slowly this might be cost-
effective, and prevent depression and subsequent admissions and
improve quality of life. Those patients, especially those with
multiple complex problems, whose disease is more rapidly
progressing (especially those with MSA and PSP), who were
approaching death, or who had continuing problems, could go on
to receive continuing palliative care in the community or in
hospice following existing care models. This patient group has low
survival, exemplified by the high death rate in follow-up, which is
already a requirement for many palliative care services for referral.
Some guidance already exists on the management of common
symptoms arising in end stage of neurological diseases, including
treatment of breathlessness, death rattle, restlessness, pain, thirst,
and depression, along with consideration of difficult decisions e.g.
fluid substitution and sedation in the terminal phase [32], and
these could be the subject of future research.
Our study is limited by the setting - one secondary and tertiary
neurology service in the south of the UK. There may well be
patients who have not been referred to neurology services, and/or
who had become too ill to attend for follow-up who were missed
from our study. However, using an established neurological centre,
with access to neurological tests and examination, including
imaging, reduces the chances of misdiagnosis of IPD, MSA and
PSP. Our study may be subject to the Hawthorne effect. Ethically
the researcher could not observe severe distress and not offer to
help in some way. On a few occasions this happened. In addition,
many staff knew that patients were being followed and may have
modified their practice. Therefore, it is likely that this study
underestimates the actual level of problems experienced by
patients and families with Parkinson’s syndromes in the commu-
nity. As our level of need was high this is worrying. Although we
identified factors that were associated with future events we cannot
assume causality. It may be that our predictive factors were
associated with other problems which actually caused the
subsequent higher levels of symptoms. However, the predictors
we identified will be useful to clinicians in identifying those patients
who may need greater subsequent support. We excluded patients
already in nursing homes, and so our findings can be extrapolated
to only home care samples. Our sample size was limited, and
attrition was slightly higher than planned, but this was an
extremely difficult to reach group requiring home interviews due
to the high levels of disability. Very little is known about the
progression of advanced, particularly stage 4/5 (Hoehn and Yahr)
Parkinson’s, MSA and PSP. We believe our study is the first to
examine longitudinal trajectories, contrasting patients with late
stage IDP, PSP and MSA, and thus provides a unique
contribution, highlighting potential service developments and
clinical indicators to identify those with greatest future need.
Figure 2. Mean total score trajectories (POS-PP, POS, PDQ-8 and HADS) by patterns of follow-up scores.
doi:10.1371/journal.pone.0046327.g002
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Conclusion
We correctly identified and studied a group of patients with late
stage disease missed in earlier research, and were able to study
them over time. Our findings of severe and continuing symptoms,
psychological and palliative distress suggest that current care is not
meeting patients’ needs, or controlling symptoms. The severity of
Figure 3. Relationship between baseline total Core-POS score and final POS-PP total score, Pain score.
doi:10.1371/journal.pone.0046327.g003
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their problems, similar to those of palliative care cancer patients,
suggests that palliative care is not being equitably offered to all
those in need. While some symptoms, such as fatigue, are
especially difficult to manage, other symptoms, such as pain
control, have growing possibilities for management in both cancer
and non cancer conditions. The Palliative care Outcome Scale
(POS) or the PDQ-8 baseline score in people with H&Y of 3 or
more, and/or a diagnosis of MSA or PSP could help to trigger
referral for increased support and palliative care. Research is
urgently needed to test symptomatic treatments and psychological
support for patients with late stage Parkinson’s Disease and related
motor disorders.
Supporting Information
Figure S1 Individual trajectories of total score of POS-
PP over the interview period. Note: Increased score
equals more symptoms.
(TIF)
Figure S2 Individual trajectories of total score of HADs-
14 over the interview period. Note: Increased score
equals greater psychological distress.
(TIF)
Figure S3 Individual trajectories of total score of PDQ-8
over the interview period. Note: Increased score equals
poorer quality of life.
(TIF)
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